ADCT vs MGNX vs RCUS vs ABBV vs TGTX

For growth investors, TG Therapeutics, Inc.

(TGTX) is the stronger pick with 87. 3% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). TG Therapeutics, Inc. (TGTX) offers the better valuation at 15. 5x trailing P/E (32. 9x forward), making it the more compelling value choice. Analysts rate ADC Therapeutics S. A. (ADCT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, TG Therapeutics, Inc.

(TGTX) is the cheapest at 15. 5x versus AbbVie Inc. at 85. 0x. On forward P/E, AbbVie Inc. is actually cheaper at 14. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +99. 6%, compared to -90. 2% for MacroGenics, Inc. (MGNX). Over 10 years, the gap is even starker: TGTX returned +434. 4% versus ADCT's -88. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 28β versus ADC Therapeutics S. A. 's 1. 84β — meaning ADCT is approximately 567% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Arcus Biosciences, Inc. (RCUS) carries a lower debt/equity ratio of 16% versus 66% for MacroGenics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TG Therapeutics, Inc.

(TGTX) is pulling ahead at 87. 3% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: TG Therapeutics, Inc. grew EPS 1747% year-over-year, compared to -10. 3% for MacroGenics, Inc.. Over a 3-year CAGR, TGTX leads at 504. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TG Therapeutics, Inc.

(TGTX) is the more profitable company, earning 72. 6% net margin versus -175. 3% for ADC Therapeutics S. A. — meaning it keeps 72. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 14. 2x forward P/E versus 32. 9x for TG Therapeutics, Inc. — 18. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADCT: 114. 3% to $7. 50.

In this comparison, ABBV (3.

3% yield) pays a dividend. ADCT, MGNX, RCUS, TGTX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 3. 3% yield, +293. 8% 10Y return). ADC Therapeutics S. A. (ADCT) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +293. 8%, ADCT: -88. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ADCT is a small-cap quality compounder stock; MGNX is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock; TGTX is a small-cap high-growth stock. ABBV pays a dividend while ADCT, MGNX, RCUS, TGTX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.